Carroll Financial Associates, Inc. - ZIOPHARM ONCOLOGY INC ownership

ZIOPHARM ONCOLOGY INC's ticker is ZIOP and the CUSIP is 98973P101. A total of 149 filers reported holding ZIOPHARM ONCOLOGY INC in Q1 2016. The put-call ratio across all filers is 0.52 and the average weighting 0.2%.

Quarter-by-quarter ownership
Carroll Financial Associates, Inc. ownership history of ZIOPHARM ONCOLOGY INC
ValueSharesWeighting
Q4 2021$6,000
-40.0%
6,0000.0%0.00%
-100.0%
Q3 2021$10,000
-33.3%
6,0000.0%0.00%0.0%
Q2 2021$15,000
-28.6%
6,0000.0%0.00%0.0%
Q1 2021$21,000
+40.0%
6,0000.0%0.00%0.0%
Q4 2020$15,0000.0%6,0000.0%0.00%0.0%
Q3 2020$15,000
-21.1%
6,0000.0%0.00%
-50.0%
Q2 2020$19,000
+35.7%
6,0000.0%0.00%
+100.0%
Q1 2020$14,000
-50.0%
6,0000.0%0.00%
-50.0%
Q4 2019$28,000
+12.0%
6,0000.0%0.00%0.0%
Q3 2019$25,000
-26.5%
6,0000.0%0.00%
-33.3%
Q2 2019$34,000
+47.8%
6,0000.0%0.00%
+50.0%
Q1 2019$23,000
+76.9%
6,0000.0%0.00%
+100.0%
Q4 2018$13,000
-31.6%
6,0000.0%0.00%
-50.0%
Q3 2018$19,000
+5.6%
6,0000.0%0.00%0.0%
Q2 2018$18,000
-21.7%
6,0000.0%0.00%
-33.3%
Q1 2018$23,000
-4.2%
6,0000.0%0.00%0.0%
Q4 2017$24,000
-38.5%
6,0000.0%0.00%
-25.0%
Q3 2017$39,000
+5.4%
6,0000.0%0.00%0.0%
Q2 2017$37,000
-2.6%
6,0000.0%0.00%
-20.0%
Q1 2017$38,000
+18.8%
6,0000.0%0.01%0.0%
Q4 2016$32,000
-3.0%
6,0000.0%0.01%0.0%
Q3 2016$33,000
+3.1%
6,0000.0%0.01%0.0%
Q2 2016$32,000
-27.3%
6,0000.0%0.01%
-37.5%
Q1 2016$44,000
+69.2%
6,000
+100.0%
0.01%
-52.9%
Q4 2014$26,0003,0000.02%
Other shareholders
ZIOPHARM ONCOLOGY INC shareholders Q1 2016
NameSharesValueWeighting ↓
Belmont Global Advisors, Inc. 2,564,925$11,132,0008.99%
Essex Woodlands Management, Inc. 2,764,908$11,330,0005.70%
Third Security, LLC 17,815,708$77,320,0003.68%
MSD Partners, L.P. 2,750,000$11,935,0000.49%
SFMG, LLC 99,850$433,0000.15%
GM Advisory Group, LLC 12,500$54,0000.06%
Geduld E E 25,000$109,0000.05%
WESTPORT RESOURCES MANAGEMENT INC 30,500$132,0000.04%
Janney Montgomery Scott LLC 335,571$1,456,378,0000.04%
WFG Advisors, LP 48,040$208,0000.03%
View complete list of ZIOPHARM ONCOLOGY INC shareholders